A modelling study released in March gives a clue at which price the jab, lenacapavir, would be worth the health department’s ...

A modelling study shows the six-monthly anti-HIV jab, lenacapavir, could end Aids in SA by 2032 - but only if between two and ...

The biggest tail risk we are facing is a full-on trade war, which is why the market reacted so negatively to the so-called ...

A modelling study shows that lenacapavir could end Aids in South Africa by 2032 – but only if between two and four million ...

While Gilead is eliminating 149 positions at its headquarters in Foster City, Roche is letting go of 108 workers at its ...

Key to 400-employee Denali's submission is the FDA allowing measurement of a type of GAG, called heparan sulfate, in ...

Tom Nolan reviews this week’s research There are so many studies published about vitamin D—about a dozen each day—it’s hard to keep up. One that stands out is a double-blind randomised controlled ...

South Florida, an area with the highest rate of HIV/AIDS in the country, is already starting to feel the effects of the Trump ...

Explore the top-performing Nasdaq 100 stocks this year as the index moves into a technical bear market this year.